Introduction: Ranitidine hydrochloride, a member of the H2-receptor antagonist class, is widely employed in treating gastrointestinal conditions like ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome by reducing gastric acid production. Microspheres, designed for extended drug delivery and enhanced bioavailability, were formulated and evaluated in this study. Aim: To develop ranitidine hydrochloride microspheres capable of prolonging drug delivery and improving bioavailability. Methods: The inotropic gelation method was utilized to prepare alginate microspheres incorporating polymers such as ethyl cellulose, sodium carboxymethyl cellulose, HPMC, and carbopol®. The resulting drug-loaded microspheres exhibited spherical rigidity after cross-linking with a 10% w/v calcium chloride solution. Evaluation parameters including Fourier transform infra-red (FTIR) analysis, precompression characteristics, percentage yield, swelling index, and drug content were determined. Results: The FTIR results obtained, showed there was no incompatibility among the excipients and the active pharmaceutical ingredient. The Scanning electron microscopy (SEM) obtained, indicated the presence of spherical particles present in the formulation. The pre-compression evaluation showed that the angle of repose ranged from 4.85 ± 0.02 to 7.22 ± 0.06o for batched F4 and F1 respectively, while the Carr’s index ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. The percentage yield ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. In vitro drug release studies revealed sustained drug release over 4 hours, with a maximum release of 69.50 ± 1.77% observed for batch F-1. Conclusion: Overall, the formulated ranitidine hydrochloride microspheres demonstrated prolonged and controlled release characteristics, indicating their potential for use in controlled drug delivery applications.
Published in | American Journal of Polymer Science and Technology (Volume 10, Issue 2) |
DOI | 10.11648/j.ajpst.20241002.12 |
Page(s) | 36-46 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Ranitidine Hydrochloride, Drug Delivery, Microspheres, Formulation, Ulcer
Ingredients (g)/Batches | F-1 | F-2 | F-3 | F-4 | F-5 | F-6 | F-7 | F-8 | F-9 |
---|---|---|---|---|---|---|---|---|---|
Ranitidine | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Sodium alginate | 1 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 | 1 | 0.8 |
Ethyl cellulose | 1 | 0.2 | 1 | - | - | - | - | - | - |
Na-CMC | - | - | - | 1 | 0.2 | 1 | - | - | - |
HPMC | - | - | - | - | - | - | 1 | 0.2 | 1 |
Acetone (ml) | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
Cacl2 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Ranitidine | |
---|---|
Odour | Choking |
Colour | White |
Taste | Bitter |
Texture | Fine powder |
Formulation code | Angle of repose (o) | Bulk density (g/ml) | Tapped density (g/ml) | Carr’s Index (%) | Hausners ratio |
---|---|---|---|---|---|
F-1 | 7.220 ± 0.06 | 0.530 ± 0.01 | 0.545 ± 0.00 | 13.90 ± 0.03 | 1.291 ± 0.18 |
F-2 | 3.657 ± 0.11 | 0.537 ± 0.02 | 0.602 ± 0.00 | 13.75 ± 0.02 | 1.056 ± 0.01 |
F-3 | 9.415 ± 0.36 | 0.511 ± 0.01 | 0.616 ± 0.01 | 14.55 ± 0.02 | 1.095 ± 0.05 |
F-4 | 4.855 ± 0.02 | 0.444 ± 0.02 | 0.502± 0.00 | 14.90 ± 0.02 | 1.035 ± 0.01 |
F-5 | 3.525 ± 0.02 | 0.507 ± 0.00 | 0.594 ± 0.01 | 15.05 ± 0.01 | 1.173 ± 0.05 |
F-6 | 4.491 ± 0.01 | 0.592 ± 0.01 | 0.627 ± 0.02 | 12.75 ± 0.01 | 1.154 ± 0.00 |
F-7 | 5.045 ± 0.02 | 0.625 ± 0.01 | 0.618 ± 0.00 | 13.04 ± 0.01 | 1.139 ± 0.01 |
F-8 | 6.627 ± 0.16 | 0.507 ± 0.00 | 0.628 ± 0.02 | 13.00 ± 0.01 | 1.265 ± 0.07 |
F-9 | 6.845 ± 0.03 | 0.623 ± 0.01 | 0.633 ± 0.01 | 13.89 ± 0.01 | 1.360 ± 0.03 |
Formulation code | Yield (%) ± SD |
---|---|
F-1 | 87.00 ± 3.53 |
F-2 | 82.5 ± 1.76 |
F-3 | 77.00 ± 0.70 |
F-4 | 81.00 ± 4.24 |
F-5 | 77.00 ± 1.41 |
F-6 | 83.00 ± 2.12 |
F-7 | 73.5 ± 2.47 |
F-8 | 84.00 ± 0.70 |
F-9 | 83.00 ± 2.21 |
Formulation code | Swelling index (%) | Drug content (%) |
---|---|---|
F-1 | 62.50 ± 0.35 | 24.50 ± 2.47 |
F-2 | 67.50 ± 1.77 | 30.50 ± 3.18 |
F-3 | 71.00 ± 0.71 | 28.00 ± 0.00 |
F-4 | 76.00 ± 1.41 | 31.00 ± 2.83 |
F-5 | 77.50 ± 3.89 | 28.50 ± 1.77 |
F-6 | 78.50 ± 3.18 | 29.00 ± 0.71 |
F-7 | 76.50 ± 4.60 | 34.00 ± 1.71 |
F-8 | 80.50 ± 0.35 | 30.50 ± 0.35 |
F-9 | 82.50 ± 1.06 | 41.50 ± 4.24 |
Time (mins)/ Batch | F-1 | F-2 | F-3 | F-4 | F-5 | F-6 | F-7 | F-8 | F-9 |
---|---|---|---|---|---|---|---|---|---|
0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
15 | 2.35 ± 0.25 | 2.10 ± 0.35 | 2.55 ± 0.35 | 2.55 ± 0.18 | 2.55 ± 0.18 | 2.35 ± 0.25 | 2.40 ± 0.07 | 2.65 ± 0.46 | 2.15 ± 0.25 |
30 | 7.60 ± 0.57 | 8.10 ± 0.07 | 7.80 ± 0.42 | 7.7 ± 0.14 | 7.65 ± 0.18 | 8.00 ± 0.35 | 7.95 ± 0.04 | 7.90 ± 0.35 | 8.20 ± 0.14 |
60 | 17.25 ± 1.59 | 7.80 ± 2.97 | 17.85 ± 2.02 | 15.10 ± 0.70 | 9.00 ± 4.24 | 7.77 ± 2.89 | 16.45 ± 1.03 | 17.55 ± 1.80 | 11.65 ± 0.11 |
90 | 35.20 ± 0.57 | 14.90 ± 0.07 | 35.00 ± 0.71 | 27.05± 2.16 | 19.85 ± 2.93 | 15.85 ± 0.81 | 36.50 ± 1.06 | 26.25± 1.59 | 15.40 ± 0.49 |
120 | 47.80 ± 0.57 | 13.65 ± 3.08 | 43.00 ± 1.41 | 35.65 ± 0.25 | 27.00 ± 6.36 | 18.20 ± 0.14 | 36.50 ± 2.12 | 33.75 ± 1.59 | 17.60 ± 0.28 |
150 | 51.00 ± 2.83 | 20.85± 0.60 | 50.00 ± 2.12 | 39.75 ± 0.18 | 29.75 ± 7.25 | 19.75 ± 0.04 | 51.25 ± 0.88 | 42.30 ± 2.62 | 19.70 ± 0.07 |
180 | 57.00 ± 4.95 | 23.45 ± 0.32 | 55.00 ± 2.47 | 48.70 ± 1.20 | 37.85 ± 6.47 | 24.00 ± 0.28 | 57.40 ± 0.42 | 51.20 ± 0.85 | 25.73 ± 0.88 |
210 | 64.00 ± 2.83 | 25.35 ± 0.46 | 65.00 ± 3.53 | 54.60 ± 0.99 | 41.35 ± 9.90 | 25.90 ± 0.42 | 62.20 ± 0.14 | 58.35 ± 0.25 | 33.05 ± 1.73 |
240 | 69.50 ± 1.77 | 29.95 ± 0.17 | 62.50 ± 1.06 | 62.40 ± 1.70 | 45.00 ± 9.98 | 29.40 ± 3.04 | 64.75 ± 1.94 | 64.75 ± 3.36 | 39.75 ± 0.53 |
Concentration (µg/ml) | Absorbance |
---|---|
0.0 | 0.0 |
1.0 | 0.107 |
2.0 | 0.200 |
3.0 | 0.283 |
4.0 | 0.371 |
5.0 | 0.456 |
6.0 | 0.539 |
Concentration (µg/ml) | Absorbance |
---|---|
0.0 | 0.0 |
6 | 0.160 |
10 | 0.289 |
15 | 0.450 |
20 | 0.590 |
25 | 0.720 |
30 | 0.870 |
GIT | Gastrointestinal Tract |
FDDS | Floating Drug Delivery Systems |
RAN | Ranitidine |
Na-CMC | Sodium Carboxylmethyl Cellulose |
FTIR | Fourier Transform Infrared |
EC | Ethyl Cellulose |
HPMC | Hydroxypropyl Methyl Cellulose |
C.I | Carr’s Index |
H.R | Hausner’s Ration |
[1] | Agrawal, A. M., Neau, S. H. and Bonate, P. L. (2003). Wet granulation fine particle ethylcellulose tablets: effect of production variables and mathematical modeling of drug release. AAPS Journal, 5, 48-60. |
[2] | Chen YC, Ho HO, Liu DZ, Siow WS, Sheu MT. (2015). Swelling/floating capability and drug release characterizations of gastro-retentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose. PLoS One 10 (1): e0116914. |
[3] | Badve, S. S., Sher, P., Korde, A., Pawar, A. P. (2007). Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. European Journal Pharmaceutical Biopharmacy, 65: 85–93. |
[4] | Bardronnet, P., Faivre, V., Pugh, W. J., Piffaretti, J. C., Falson, F. (2006). Gastroretentive dosage forms: overview and special case of Helicobacter pylori. Journal Control Release. 111: 1–18. |
[5] | Batra, D., Kakar, S., Singh, R., Nautiyal, U., (2012). Magnetic microspheres as a targeted drug delivery system: An overview, Jddr. 1(3): 1-1. |
[6] | Bakowsky H, Richter T, Kneuer C, Hoekstra D, Rothe U, Bendas G. (2008). Adhesion characteristics and stability assessment of lectin-modified liposomes for site-specific drug delivery. Biochim Biophys Acta (1): 242-9. |
[7] | Shoufeng Li, Yie W. Chien, Bruce P. Daggy and Haresh L. (2001). Statistical optimization of gastric floating system for oral controlled delivery AAPS Pharm Sci Tech. 2(1): 123-130. |
[8] | Chauhan, B., Shimpi, S., Mahadik, K. R., Paradkar, A. (2004). Preparation and evaluation of floating risedronate sodium Gelucire 39/01 matrices. Acta Pharm. 54: 205–14. |
[9] | Jaimini, M., Rana, A. C., Tanwar, Y. S. (2007). Formulation and evaluation of famotidine floating tablets. Curr Drug Deliv. 4: 51–5. |
[10] | Jain, S. K., Agrawal, G. P., Jain, N. K. (2006a). A novel calcium silicate-based microspheres of repaglinide: in vivo investigations. Journal Control Release, 113: 111–6. |
[11] | Gayathridevi M, J. Adlin Jino Nesalin and T. Tamizh Man. (2016). A review of Floating Microspheres. International journal of research in pharmacy and chemistry. 6(3), 501-510. |
[12] |
Julan, M., Desai, U., Parikh, J. R., Parikh, R. H. (2005). Floating drug delivery systems: an approach to gastroretention. 2005. Available online at:
http://www.pharmainfo.net accessed on 27 Sep, 2009. |
[13] | Hirtz, J. (1985). The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. British Journal of Clinical Pharmacology, (19), 775-83S. |
[14] | Patel, V., Patel, N., and Yeole, P. (2005). Studies on formulation and evaluation of ranitidine floating tablets. Indian Journal of Pharmaceutical Sciences, (67), 703. |
[15] | Mayavanish, A. and Gajjar, S. (2008). Floating drug delivery sysytems to increase gastric retention of drugs: A Review. Research Journal of Pharmacy and Technology, (1), 345-348. |
[16] | Oth M., Frranz, M., Timmermans, J. and Moes, A. (1992). The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol. Pharmaceutical Research, (9), 298-302. |
[17] | Chaudhari, A., Jadhav, K. R., Dr. Kadam, V. J., (2010). An over view: Microspheres as a nasal drug delivery system, International Journal Pharmaceutical Science Review Research, 5(1): 8-17. |
[18] | Alagusundaram, M., Chetty, C. M. S., Umashankari, K., Badarinath, A. V., Lavanya, C., Ramkanth, S. (2009). Microspheres as a novel drug delivery sytem- A review, International Journal Chemistry Technology Research, 1(3): 526-34. |
[19] | Jamini, M. and Rawat, S. (2013). A review on microsphere, Res. J. Pharm. boil. Chem. Sci., 4(1): 1223-33. |
APA Style
Andrew, E. C., Chidera, A. C., Ekemezie, O. J., Pauline, O. N., Chinedu, N. E., et al. (2024). Preparation and Evaluation of Ranitidine Hydrochloride Floating Microspheres. American Journal of Polymer Science and Technology, 10(2), 36-46. https://doi.org/10.11648/j.ajpst.20241002.12
ACS Style
Andrew, E. C.; Chidera, A. C.; Ekemezie, O. J.; Pauline, O. N.; Chinedu, N. E., et al. Preparation and Evaluation of Ranitidine Hydrochloride Floating Microspheres. Am. J. Polym. Sci. Technol. 2024, 10(2), 36-46. doi: 10.11648/j.ajpst.20241002.12
AMA Style
Andrew EC, Chidera AC, Ekemezie OJ, Pauline ON, Chinedu NE, et al. Preparation and Evaluation of Ranitidine Hydrochloride Floating Microspheres. Am J Polym Sci Technol. 2024;10(2):36-46. doi: 10.11648/j.ajpst.20241002.12
@article{10.11648/j.ajpst.20241002.12, author = {Ezegbe Chekwube Andrew and Anikwe Celestine Chidera and Okorie James Ekemezie and Okafor Nnedimma Pauline and Nwankwo Emmanuel Chinedu and Onunkwo Chukwunwike Godswill}, title = {Preparation and Evaluation of Ranitidine Hydrochloride Floating Microspheres }, journal = {American Journal of Polymer Science and Technology}, volume = {10}, number = {2}, pages = {36-46}, doi = {10.11648/j.ajpst.20241002.12}, url = {https://doi.org/10.11648/j.ajpst.20241002.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpst.20241002.12}, abstract = {Introduction: Ranitidine hydrochloride, a member of the H2-receptor antagonist class, is widely employed in treating gastrointestinal conditions like ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome by reducing gastric acid production. Microspheres, designed for extended drug delivery and enhanced bioavailability, were formulated and evaluated in this study. Aim: To develop ranitidine hydrochloride microspheres capable of prolonging drug delivery and improving bioavailability. Methods: The inotropic gelation method was utilized to prepare alginate microspheres incorporating polymers such as ethyl cellulose, sodium carboxymethyl cellulose, HPMC, and carbopol®. The resulting drug-loaded microspheres exhibited spherical rigidity after cross-linking with a 10% w/v calcium chloride solution. Evaluation parameters including Fourier transform infra-red (FTIR) analysis, precompression characteristics, percentage yield, swelling index, and drug content were determined. Results: The FTIR results obtained, showed there was no incompatibility among the excipients and the active pharmaceutical ingredient. The Scanning electron microscopy (SEM) obtained, indicated the presence of spherical particles present in the formulation. The pre-compression evaluation showed that the angle of repose ranged from 4.85 ± 0.02 to 7.22 ± 0.06o for batched F4 and F1 respectively, while the Carr’s index ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. The percentage yield ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. In vitro drug release studies revealed sustained drug release over 4 hours, with a maximum release of 69.50 ± 1.77% observed for batch F-1. Conclusion: Overall, the formulated ranitidine hydrochloride microspheres demonstrated prolonged and controlled release characteristics, indicating their potential for use in controlled drug delivery applications. }, year = {2024} }
TY - JOUR T1 - Preparation and Evaluation of Ranitidine Hydrochloride Floating Microspheres AU - Ezegbe Chekwube Andrew AU - Anikwe Celestine Chidera AU - Okorie James Ekemezie AU - Okafor Nnedimma Pauline AU - Nwankwo Emmanuel Chinedu AU - Onunkwo Chukwunwike Godswill Y1 - 2024/07/08 PY - 2024 N1 - https://doi.org/10.11648/j.ajpst.20241002.12 DO - 10.11648/j.ajpst.20241002.12 T2 - American Journal of Polymer Science and Technology JF - American Journal of Polymer Science and Technology JO - American Journal of Polymer Science and Technology SP - 36 EP - 46 PB - Science Publishing Group SN - 2575-5986 UR - https://doi.org/10.11648/j.ajpst.20241002.12 AB - Introduction: Ranitidine hydrochloride, a member of the H2-receptor antagonist class, is widely employed in treating gastrointestinal conditions like ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome by reducing gastric acid production. Microspheres, designed for extended drug delivery and enhanced bioavailability, were formulated and evaluated in this study. Aim: To develop ranitidine hydrochloride microspheres capable of prolonging drug delivery and improving bioavailability. Methods: The inotropic gelation method was utilized to prepare alginate microspheres incorporating polymers such as ethyl cellulose, sodium carboxymethyl cellulose, HPMC, and carbopol®. The resulting drug-loaded microspheres exhibited spherical rigidity after cross-linking with a 10% w/v calcium chloride solution. Evaluation parameters including Fourier transform infra-red (FTIR) analysis, precompression characteristics, percentage yield, swelling index, and drug content were determined. Results: The FTIR results obtained, showed there was no incompatibility among the excipients and the active pharmaceutical ingredient. The Scanning electron microscopy (SEM) obtained, indicated the presence of spherical particles present in the formulation. The pre-compression evaluation showed that the angle of repose ranged from 4.85 ± 0.02 to 7.22 ± 0.06o for batched F4 and F1 respectively, while the Carr’s index ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. The percentage yield ranged from 73.5 ± 2.47% to 87.00 ± 3.53% for batches F-7 and F-1 respectively. In vitro drug release studies revealed sustained drug release over 4 hours, with a maximum release of 69.50 ± 1.77% observed for batch F-1. Conclusion: Overall, the formulated ranitidine hydrochloride microspheres demonstrated prolonged and controlled release characteristics, indicating their potential for use in controlled drug delivery applications. VL - 10 IS - 2 ER -